FILSPARI (sparsentan) tablets, for oral use Initial U.S. Approval: 2023
FILSPARI is a prescription medicine to lower protein in the urine (proteinuria) in adults with primary IgA nephropathy who are at risk of their disease quickly getting worse.
| Brand Name: | FILSPARI |
| Generic Name: | sparsentan |
| Strength: | Tablets: 200 mg and 400 mg |
| Manufacturer: | Travere Therapeutics |
| Approved By: | EMA, USFDA |
Source Details: Patient Information
IPN, New Delhi can facilitate patient to import of “FILSPARI (sparsentan) tablets” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for FILSPARI (sparsentan) tablets price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.
Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.